Breaking News Instant updates and real-time market news.

PFE

Pfizer

$42.25

-0.33 (-0.78%)

, RIG

Transocean

$8.86

0.12 (1.37%)

10:16
02/20/19
02/20
10:16
02/20/19
10:16

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) resumed with a Neutral from Sell at Citi with analyst Andrew Baum saying the recent pullback in the stock, along with the 5%-8% 2019-2021 consensus estimate reductions, gives him the opportunity to close his Sell rating. 2. Transocean (RIG) and Diamond Offshore (DO) were upgraded to Overweight from Underweight at Barclays. 3. American Axle (AXL) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy citing progress with restructuring, GM's (GM) truck cycle, and balance sheet deleveraging. 4. Credit Suisse (CS) upgraded to Hold from Sell at Berenberg. 5. Ipsen (IPSEY) upgraded to Neutral from Sell at Goldman Sachs with analyst Diana Na citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

PFE

Pfizer

$42.25

-0.33 (-0.78%)

RIG

Transocean

$8.86

0.12 (1.37%)

DO

Diamond Offshore

$10.65

0.36 (3.50%)

AXL

American Axle

$16.92

0.32 (1.93%)

CS

Credit Suisse

$11.91

0.005 (0.04%)

IPSEY

Ipsen

$0.00

(0.00%)

  • 20

    Feb

  • 03

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    May

PFE Pfizer
$42.25

-0.33 (-0.78%)

02/20/19
SBSH
02/20/19
UPGRADE
Target $41
SBSH
Neutral
Pfizer resumed with a Neutral from Sell at Citi
Citi analyst Andrew Baum resumed coverage of Pfizer following a period of restriction and upgraded the shares to Neutral from Sell. He also boosted his price target for the shares to $41 from $37. The analyst says the recent pullback in the stock, along with the 5%-8% 2019-2021 consensus estimate reductions, gives him the opportunity to close his Sell rating. He believes management action on business development, cost saving or moves to better monetize Pfizer's Established Product business are likely near-term drivers of the stock.
01/31/19
01/31/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Outperform from Neutral at Credit Suisse and to Buy from Hold at Argus. 2. Tiffany (TIF) upgraded to Overweight from Neutral at Atlantic Equities with analyst Daniela Nedialkova saying the pullback has been largely driven by macro concerns while fundamentals of the brand are strong and preliminary FY19 guidance is conservative. 3. Scotts Miracle-Gro (SMG) upgraded to Neutral from Underweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 4. Geron (GERN) upgraded to Buy from Neutral at B. Riley FBR with analyst George Zavoico saying he believes investors should focus on the pivotal Phase III trial of imetelstat. 5. Ralph Lauren (RL) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Dana Telsey saying the company's improving sakes, combined with ongoing margin expansion, should bolster its earnings. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/31/19
ARGS
01/31/19
UPGRADE
Target $55
ARGS
Pfizer upgraded to Buy from Hold at Argus
Argus analyst David Toung upgraded Pfizer (PFE) to Buy with a price target of $55, saying he anticipates an upward revenue inflection point in 2021 after flat sales in the second half of 2019 and first half of 2020. After cycling through Lyrica loss of exclusivity over the next year, the analyst anticipates Pfizer to benefit from optimized portfolio of assets as it completes its consumer healthcare business joint venture with GlaxoSmithKline (GSK). Toung adds that while he does not "expect major transformational deals", he does see the management pursuing "acquisitions and divestitures that improve long-term profitability".
01/31/19
01/31/19
UPGRADE
Target $47

Outperform
Pfizer upgraded to Outperform on new product story at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Pfizer to Outperform from Neutral and raised his price target on the shares to $47 from $45. The analyst notes that Pfizer has been working through a dark period with extensive patent expirations that have hampered the company's ability to grow, but that period is now nearing an end. Further, the analyst believes the company's new product story with multiple marketed and pipeline assets may be underappreciated.
RIG Transocean
$8.86

0.12 (1.37%)

02/20/19
LEHM
02/20/19
UPGRADE
Target $10
LEHM
Overweight
Transocean upgraded to Overweight from Underweight at Barclays
Barclays analyst J. David Anderson double upgraded Transocean to Overweight from Underweight and raised his price target for the shares to $10 from $8. The analyst says that while it has been a while since he's recommended owning the offshore oilfield service names, after almost five years of a downturn, a "transformed" offshore industry is "starting to emerge." He expects 2019 to be a transition year with 2020 "setting up to be the start of a multi-year growth trajectory." He views shares of Transocean as undervalued at current levels.
02/20/19
LEHM
02/20/19
UPGRADE
LEHM
Overweight
Transocean upgraded to Overweight from Underweight at Barclays
Barclays analyst David Anderson double upgraded Transocean to Overweight from Underweight.
01/09/19
DNBM
01/09/19
UPGRADE
DNBM
Buy
Transocean upgraded to Buy from Hold at DNB Markets
12/28/18
WELS
12/28/18
NO CHANGE
WELS
Wells sees 'rocky times ahead' for Oil Services and Equipment market
Emerging data points suggest "rocky times ahead" for the North American Oil Services and Equipment market in early 2019, Wells Fargo analyst Judson Bailey tells investors in a research note. As oil prices and macro conditions have weakened to end 2018, a number of recent conversations suggest a "quickly deteriorating" outlook for exploration and production budgets, activity levels and pricing over the first few months of 2019, adds the analyst. He believes the case for "much needed consolidation" across the U.S. oilfield services landscape "has never been greater."
DO Diamond Offshore
$10.65

0.36 (3.50%)

02/20/19
LEHM
02/20/19
UPGRADE
LEHM
Overweight
Diamond Offshore upgraded to Overweight from Underweight at Barclays
Barclays analyst David Anderson double upgraded Diamond Offshore to Overweight from Underweight.
02/20/19
LEHM
02/20/19
UPGRADE
Target $12
LEHM
Overweight
Diamond Offshore upgraded to Overweight from Underweight at Barclays
Barclays analyst J. David Anderson double upgraded Diamond Offshore Drilling to Overweight from Underweight while lowering his price target for the shares to $12 from $14. The analyst says that while it has been a while since he's recommended owning the offshore oilfield service names, after almost five years of a downturn, a "transformed" offshore industry is "starting to emerge." He expects 2019 to be a transition year with 2020 "setting up to be the start of a multi-year growth trajectory." He views shares of Diamond Offshore as undervalued at current levels.
02/04/19
FERN
02/04/19
UPGRADE
FERN
Buy
Diamond Offshore upgraded to Buy from Accumulate at Fearnley
01/28/19
PART
01/28/19
UPGRADE
PART
Buy
Diamond Offshore upgraded to Buy from Hold at Pareto
AXL American Axle
$16.92

0.32 (1.93%)

12/10/18
KEYB
12/10/18
INITIATION
KEYB
Sector Weight
American Axle initiated with a Sector Weight at KeyBanc
KeyBanc started American Axle with a Sector Weight rating.
02/20/19
BOFA
02/20/19
UPGRADE
BOFA
Buy
American Axle upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst John Murphy upgraded American Axle to Buy from Neutral with a $20 price target citing progress with restructuring, GM's truck cycle, and balance sheet deleveraging. Murphy expects the integration of MPG to realize benefits through 2019 and drive incremental cost and revenue synergies. The analyst also expects GM's truck launch to provide support and potential upside through 1H 2020 and for reasonably strong free cash flow to strengthen the balance sheet.
01/07/19
MSCO
01/07/19
NO CHANGE
MSCO
Morgan Stanley sees most, if not all, auto suppliers guiding below consensus
Ahead of the Detroit auto show, Morgan Stanley analyst Armintas Sinkevicius said he expects that most, if not all, auto suppliers will provide 2019 guidance that is lower than consensus. He sees the most downside risk to Visteon (VC) and Adient (ADNT), estimating that they may guide adjusted EBITDA 6.4% and 5.0% below consensus, respectively. Not everyone will provide guidance at the show, as American Axle (AXL) and Delphi Technologies (DLPH) gave guidance with Q3 earnings and Aptiv (APTV) and BorgWarner (BWA) plan to wait for Q4 earnings, added Sinkevicius. He estimates that, on average, the auto suppliers will guide to 1.5% revenue growth and -25 bps of margin contraction in 2019, adding that his concern is that the guidance provided at Detroit may not sufficiently de-risk figures. Others in the space include Lear (LEA), Tenneco (TEN) and Magna (MGA).
12/13/18
DBAB
12/13/18
INITIATION
Target $11
DBAB
Hold
American Axle initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Emmanuel Rosner started American Axle with a Hold rating and $11 price target.
CS Credit Suisse
$11.91

0.005 (0.04%)

11/23/18
RBCM
11/23/18
DOWNGRADE
RBCM
Sector Perform
Credit Suisse downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Anke Reingen downgraded Credit Suisse to Sector Perform and lowered her price target for the shares to 15 francs from 17.50 francs. A re-rating higher of shares in the near-term will be difficult amid pressure on revenue and limited scope to cut more costs, Reingen tells investors in a research note. The analyst reduced her fiscal 2019 estimates for Credit Suisse by 10% to reflect current market trends.
02/20/19
BREN
02/20/19
UPGRADE
BREN
Hold
Credit Suisse upgraded to Hold from Sell at Berenberg
11/21/18
11/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lowe's (LOW) downgraded to Hold from Buy at Stifel with analyst John Baugh saying the company's "poor" Q3 results indicate near term execution risks are higher and the macro backdrop is unlikely to improve in the near term either. 2. Goldman Sachs (GS) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Betsy Graseck citing the risks and uncertainties related to the bank being investigated for its role in raising funds for 1MDB. 3. Credit Suisse (CS) downgraded to Market Perform from Outperform at Keefe Bruyette. 4. Swatch Group (SWGAY) was downgraded to Sell from Neutral at UBS and to Sector Perform from Outperform at RBC Capital. 5. Alliant Energy (LNT) downgraded to Underperform from Neutral at BofA/Merrill with analyst Julien Dumoulin-Smith citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/23/18
RBCM
11/23/18
DOWNGRADE
RBCM
Sector Perform
Credit Suisse downgraded to Sector Perform from Outperform at RBC Capital
IPSEY Ipsen
$0.00

(0.00%)

09/21/18
PIPR
09/21/18
NO CHANGE
Target $29
PIPR
Overweight
Piper Jaffray reiterates Overweight rating on Exelixis after CHMP decision
After Ipsen (IPSEY) announced a positive CHMP decision for Cabometyx as a monotherapy for the treatment of hepatocellular carcinoma, Piper Jaffray analyst Edward Tenthoff noted that Exelixis (EXEL) is eligible for tiered royalties of 22-26% after $100M in sales of the drug in Europe. He expects final EMA approval in coming months and also expects the FDA to approve Cabometyx in liver cancer by the January 14 PDUFA date, Tenthoff tells investors. He reiterated an Overweight rating and $29 price target on Exelixis shares.
09/28/18
GSCO
09/28/18
INITIATION
GSCO
Sell
Ipsen initiated with a Sell at Goldman Sachs
10/08/18
JPMS
10/08/18
DOWNGRADE
JPMS
Underweight
Ipsen downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Ipsen to Underweight with a price target of EUR 120. The analyst believes the risk/reward is skewed to the downside with the shares "priced for perfection."
02/19/19
GSCO
02/19/19
UPGRADE
GSCO
Neutral
Ipsen upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Diana Na upgraded Ipsen to Neutral citing valuation. The analyst sees a more balanced risk/reward following the stock's recent underperformance.

TODAY'S FREE FLY STORIES

03:05
09/18/19
09/18
03:05
09/18/19
03:05
General news
FX Update: The dollar majors have been holding narrow ranges »

FX Update: The dollar…

03:00
09/18/19
09/18
03:00
09/18/19
03:00
General news
FX Update: The dollar majors have been holding narrow ranges »

FX Update: The dollar…

01:50
09/18/19
09/18
01:50
09/18/19
01:50
General news
FX Action: »

FX Action: The USD is…

01:45
09/18/19
09/18
01:45
09/18/19
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

01:40
09/18/19
09/18
01:40
09/18/19
01:40
General news
FOMC preview: »

FOMC preview: a quarter…

01:40
09/18/19
09/18
01:40
09/18/19
01:40
General news
Fed SEP forecasts: t »

Fed SEP forecasts: the…

TBIO

Translate Bio

$11.01

0.405 (3.82%)

21:06
09/17/19
09/17
21:06
09/17/19
21:06
Syndicate
Translate Bio 9M share Spot Secondary priced at $10.00 »

Citi, Jefferies and SVB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SWK

Stanley Black & Decker

$144.45

0.73 (0.51%)

21:05
09/17/19
09/17
21:05
09/17/19
21:05
Downgrade
Stanley Black & Decker rating change at KeyBanc »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

LEN

Lennar

$53.10

-0.23 (-0.43%)

21:02
09/17/19
09/17
21:02
09/17/19
21:02
Downgrade
Lennar rating change at KeyBanc »

Lennar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 02

    Oct

WHR

Whirlpool

$152.15

3.4 (2.29%)

21:02
09/17/19
09/17
21:02
09/17/19
21:02
Downgrade
Whirlpool rating change at KeyBanc »

Whirlpool downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TELL

Tellurian

$8.33

-0.1 (-1.19%)

20:44
09/17/19
09/17
20:44
09/17/19
20:44
Initiation
Tellurian initiated  »

Tellurian initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

20:41
09/17/19
09/17
20:41
09/17/19
20:41
Initiation
NextDecade initiated  »

NextDecade initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LINX

Linx S.A.

$7.74

0.22 (2.93%)

20:32
09/17/19
09/17
20:32
09/17/19
20:32
Recommendations
Linx S.A. analyst commentary at Jefferies »

Linx S.A. offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Conference/Events
Morgan Stanley steel analyst to hold an analyst/industry conference call »

China Materials Analyst…

GIS

General Mills

$55.03

0.48 (0.88%)

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 01

    Oct

ROAD

Construction Partners

$14.39

-0.42 (-2.84%)

20:10
09/17/19
09/17
20:10
09/17/19
20:10
Syndicate
Construction Partners 5M share Secondary priced at $14.25 »

Construction Partners 5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 18

    Sep

NVST

Envista

$0.00

(0.00%)

19:58
09/17/19
09/17
19:58
09/17/19
19:58
Syndicate
Envista 26.77M share IPO priced at $22.00 »

The deal priced inside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

INVH

Invitation Homes

$28.49

0.31 (1.10%)

19:51
09/17/19
09/17
19:51
09/17/19
19:51
Syndicate
Invitation Homes 44M share Spot Secondary priced at $28.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

, NCMI

National CineMedia

$8.35

0.25 (3.09%)

19:49
09/17/19
09/17
19:49
09/17/19
19:49
Hot Stocks
AMC Entertainment corrects 'inaccurate' statement by National CineMedia »

AMC Entertainment (AMC)…

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

NCMI

National CineMedia

$8.35

0.25 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

BA

Boeing

$384.61

5.74 (1.52%)

19:01
09/17/19
09/17
19:01
09/17/19
19:01
Hot Stocks
House panel invites Boeing CEO to testify on 737 MAX »

Chair of the House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

O

Realty Income

$75.76

1.81 (2.45%)

18:56
09/17/19
09/17
18:56
09/17/19
18:56
Hot Stocks
Realty Income raises monthly cash dividend to 22.7c per share from 22.65c »

Realty Income Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

, CDW

CDW

$113.91

0.94 (0.83%)

18:54
09/17/19
09/17
18:54
09/17/19
18:54
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: NewLink (NLNK) up…

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

CDW

CDW

$113.91

0.94 (0.83%)

TELL

Tellurian

$8.33

-0.1 (-1.19%)

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

FDX

FedEx

$173.53

-0.14 (-0.08%)

XPO

XPO Logistics

$73.83

-0.76 (-1.02%)

CHWY

Chewy

$30.20

-0.2 (-0.66%)

ADBE

Adobe

$284.59

1.54 (0.54%)

IOTS

Adesto Technologies

$10.63

-0.66 (-5.85%)

PTCT

PTC Therapeutics

$43.26

0.27 (0.63%)

TBIO

Translate Bio

$11.01

0.405 (3.82%)

ACAD

Acadia

$42.60

-1.45 (-3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 23

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 23

    Oct

  • 27

    Oct

  • 13

    Nov

  • 18

    Sep

  • 18

    Sep

  • 18

    Sep

YUMA

Yuma Energy

$5.08

-0.05 (-0.97%)

18:51
09/17/19
09/17
18:51
09/17/19
18:51
Hot Stocks
Yuma Energy enters forbearance agreement with lender YE Investment »

Yuma Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$284.59

1.54 (0.54%)

18:45
09/17/19
09/17
18:45
09/17/19
18:45
Hot Stocks
Adobe CEO: We experienced growth across all of our segments »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Oct

  • 27

    Oct

ARAY

Accuray

$3.09

-0.03 (-0.96%)

18:37
09/17/19
09/17
18:37
09/17/19
18:37
Hot Stocks
Data in Lancet Oncology discloses lower toxicity for Accuray Cyberknife patients »

Accuray announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.